Newsroom

Industry News

8 May

Cytori Therapeutics Announces Inducement Grants for New Employees

SAN DIEGO, May 05, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (the “Company”), announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options on May 4, 2017 to eight (8) new employees (the “Optionees”) exercisable for an aggregate of up to 24,500...

Read more

8 May

Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., May 08, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced today that the Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for...

Read more

4 May

Protea and Proteos Announce Co-Marketing Agreement

MORGANTOWN, W.Va. and KALAMAZOO, Mich., May 4, 2017 /PRNewswire/ — Protea Biosciences Group, Inc. (PRGB) (“Protea”) and Proteos, Inc. (“Proteos”) announced today that they have entered into a joint co-marketing agreement.  This mutual partnership allows Protea to combine Proteos’ protein production capabilities alongside Protea’s proprietary bioanalytical services, and allows Proteos...

Read more

4 May

CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11

NEWARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, May 11th at 4:30...

Read more

4 May

Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017

FREMONT, Calif., May 4, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release first quarter 2017 financial and operational results on Thursday, May 11, 2017 after the close of the U.S. financial markets....

Read more

3 May

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — – Initiation of Phase 3 registrational study expected in second half of this year – Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients BioLineRx Ltd. (NASDAQ/TASE: BLRX, BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and...

Read more

Page 5 of 234« First...34567...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address